Genentech to Invest US$750 Million in Hillsboro, Oregon, USA

Introduction:

Genentech has announced plans to invest US$750 million to expand its manufacturing facility in Hillsboro, Oregon, USA.

Features:

The project involves expanding the existing manufacturing facility in Hillsboro by 211,000 square feet, doubling the size of the current site.

The expansion will add device fill-finish capabilities, including the manufacturing of combination products that integrate medicines with delivery devices.

The facility will include flexible filling capabilities for both high- and low-volume production. Manufacturing activities will initially support medicines for oncology, neurology and immunology.

The development will incorporate digital technologies, artificial intelligence (AI), automation and robotics into manufacturing operations. It will also include a digital twin for real-time monitoring of production processes and continuous improvement.

The expanded facility will become part of the existing US manufacturing network, which includes drug product manufacturing, packaging, distribution and personalised therapies.

Commercial operations at the expanded site are expected to begin in 2031.

Specifications:

Name

Genentech

Type

New Construction

Budget

US$750 million

Year

2031